These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10468735)

  • 21. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer.
    Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K
    J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
    Lin YL; Sun G; Liu XQ; Li WP; Ma JG
    J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1).
    von Mensdorff-Pouilly S; Gourevitch MM; Kenemans P; Verstraeten AA; van Kamp GJ; Kok A; van Uffelen K; Snijdewint FG; Paul MA; Meijer S; Hilgers J
    Tumour Biol; 1998; 19(3):186-95. PubMed ID: 9591045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
    Murray A; Clinton O; Earl H; Price M; Moore A
    Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate.
    Qu CF; Li Y; Song YJ; Rizvi SM; Raja C; Zhang D; Samra J; Smith R; Perkins AC; Apostolidis C; Allen BJ
    Br J Cancer; 2004 Dec; 91(12):2086-93. PubMed ID: 15599383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer.
    Murray A; Simms MS; Scholfield DP; Vincent RM; Denton G; Bishop MC; Price MR; Perkins AC
    J Nucl Med; 2001 May; 42(5):726-32. PubMed ID: 11337567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MUC1 serum assays in breast cancer: tumor specificities and reference levels.
    Bjerner J; Norum LF; Nilsson O; Nustad K
    Tumour Biol; 2002; 23(6):315-23. PubMed ID: 12677089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ectopic human chorionic gonadotrophin (HCG) production: is the detection by serum analysis of HCG of clinical relevance in transitional cell carcinoma of the bladder?
    Smith DJ; Evans HJ; Newman J; Chapple CR
    Br J Urol; 1994 Apr; 73(4):409-12. PubMed ID: 8199829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel monoclonal antibody, H9, directed against the core protein of MUC1 mucin.
    Hamada H; Kohno N; Yokoyama A; Kondo K; Yang SZ; Hiwada K; Watanabe K; Miyake M
    Oncol Rep; 2000; 7(2):225-32. PubMed ID: 10671662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer.
    Simms MS; Murray A; Denton G; Scholfield DP; Price MR; Perkins AC; Bishop MC
    Urol Res; 2001 Feb; 29(1):13-9. PubMed ID: 11310209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
    Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
    Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The test system to identify mucin MUC1 in human blood serum using the technique of immune-enzyme analysis based on monoclonal antibody ICO25].
    Karmakova TA; Vorontsova MS; Skripnik VV; Bezborodova OA; Iakubovskaia RI
    Klin Lab Diagn; 2012 Feb; (2):53-6. PubMed ID: 22624465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595.
    Hughes OD; Bishop MC; Perkins AC; Wastie ML; Denton G; Price MR; Frier M; Denley H; Rutherford R; Schubiger PA
    J Clin Oncol; 2000 Jan; 18(2):363-70. PubMed ID: 10637251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence.
    Hamada T; Matsukita S; Goto M; Kitajima S; Batra SK; Irimura T; Sueyoshi K; Sugihara K; Yonezawa S
    J Clin Pathol; 2004 Aug; 57(8):813-21. PubMed ID: 15280401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma.
    Retz M; Lehmann J; Röder C; Plötz B; Harder J; Eggers J; Pauluschke J; Kalthoff H; Stöckle M
    Cancer Res; 1998 Dec; 58(24):5662-6. PubMed ID: 9865718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum markers CASA and CA 15-3 in ovarian cancer: all MUC1 assays are not the same.
    Devine PL; McGuckin MA; Quin RJ; Ward BG
    Tumour Biol; 1994; 15(6):337-44. PubMed ID: 7997805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration.
    Chhieng DC; Benson E; Eltoum I; Eloubeidi MA; Jhala N; Jhala D; Siegal GP; Grizzle WE; Manne U
    Cancer; 2003 Dec; 99(6):365-71. PubMed ID: 14681945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and application of a double- antibody sandwich ELISA kit for the detection of serum MUC1 in lung cancer patients.
    Wang J; Zhang S; Ni W; Zhai X; Xie F; Yuan H; Gao S; Tai G
    Cancer Biomark; 2016; 17(4):369-376. PubMed ID: 27636855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
    Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
    BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.